Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Relmada Therapeutics ( (RLMD) ) has shared an update.
On September 10, 2025, Relmada Therapeutics issued a letter to shareholders highlighting significant progress in its strategic initiatives. The company has expanded its portfolio with two promising Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer and sepranolone for compulsivity disorders like Prader-Willi Syndrome. NDV-01 showed a 91% complete response rate in a Phase 2 study, and preparations for a Phase 3 trial are underway. The company has strengthened its team with experts in bladder cancer to support this development. Sepranolone has shown positive proof-of-concept results in Tourette’s syndrome, and a Phase 2 study for Prader-Willi Syndrome is planned for 2026. These advancements position Relmada well for future growth and value creation.
The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Lead candidates NDV-01 and sepranolone are advancing through mid-stage clinical development with the potential to address significant unmet needs.
Average Trading Volume: 700,461
Technical Sentiment Signal: Sell
Current Market Cap: $53.11M
For an in-depth examination of RLMD stock, go to TipRanks’ Overview page.